drugset / Trial / NCT05718544

Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia and Long-term Outcomes

NCT05718544

Phase 4 Completed 199 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Chronic postsurgical pain (CPSP) refers to pain that occurs or increases after surgery and lasts longer than 3 months. Severe postoperative acute pain is one of the major risk factors of CPSP. Spine surgery brings severe postoperative pain due to large trauma and long duration. Ketamine and esketamine are N-methyl-D-aspartate receptor antagonists; they have anti-hyperalgesic effects and may reduce CPSP. Dexmedetomidine is an alpha 2-adrenoceptor agonist with sedative, anxiolytic, and analgesic effect; it is frequently used as an adjuvant to postoperative analgesia. In a previous trial of the investigators, 200 patients following scoliosis correction surgery were randomzied to receive opioid analgsia supplemented with either mini-dose esketamine-dexmedetomidine combination or placebo. The results showed that esketamine-dexmedetomidine supplement analgesia significantly improved analgesia and sleep quality after surgery. This study is designed to test the hypothesis that mini-dose esketamine-dexmedetomidine supplemented analgesia may reduce CPSP at 2 years after scoliosis correction surgery.

Timeline

Start
2023-01-30
Primary completion
2023-09-07
Completion
2023-09-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 200 ug
Subject Esketamine Other / unclassified 50 mg
Background Sufentanil Other / unclassified 4 ug/kg